Articles from Belenos Biosciences Inc.

Belenos Pipeline Updates: First Clinical Data from Lead Asset BEL512, a Long-lasting Bispecific Targeting TSLP and IL-13, Second Asset BEL536, a First-in-class Long-acting Bispecific Targeting OX40L and IL-13, Phase 1 to Start 1Q2026

Belenos Biosciences Inc.:

By Belenos Biosciences Inc. · Via Business Wire · November 10, 2025